Hyperthermia enhances the effect of β-lapachone to cause γh2AX formations and cell death in human osteosarcoma cells

International Journal of Hyperthermia

Volumn 27, Issue 1, 2011, Pages 53-62

  Hori, Takeshi ^a,b   Kondo, Takashi ^b   Lee, Hyemi ^c   Song, Chang W ^a   Park, Heon Joo ^a,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TOYAMA   (Japan)

^c Inha University School of Medicine   (South Korea)

Author keywords

lapachone; H2AX; hyperthermia; NQO1; osteosarcoma

Indexed keywords

BETA LAPACHONE; HISTONE H2AX; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE PHASE; CELL CYCLE REGULATION; CELL SURVIVAL; CYTOTOXICITY; DNA DAMAGE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; OSTEOSARCOMA CELL; PROTEIN EXPRESSION; UPREGULATION;

CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; HISTONES; HUMANS; HYPERTHERMIA, INDUCED; NAD(P)H DEHYDROGENASE (QUINONE); NAPHTHOQUINONES; OSTEOSARCOMA;

EID: 79251495155     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656736.2010.513361     Document Type: Article

References (40)

1. Pardee AB, Li YZ, Li CJ. Cancer therapy with beta-lapachone. Curr Cancer Drug Targets 2002;2:227-242.
2. Planchon SM, Pink JJ, Tagliarino C, Bornmann WG, Varnes ME, Boothman DA. Beta-lapachone-induced apoptosis in human prostate cancer cells: Involvement of NQO1/xip3. Exp Cell Res 2001;267:95-106.
3. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, Boothman DA. NAD(P)H:quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J Biol Chem 2000:275:5416-5424.
4. Tagliarino C, Pink JJ, Dubyak GR, Nieminen AL, Boothman DA. Calcium is a key signaling molecule in beta-lapachone-mediated cell death. J Biol Chem 2001; 276:19150-19159.
5. Pink JJ, Wuerzberger-Davis S, Tagliarino C, Planchon SM, Yang X, Froelich CJ, Boothman DA. Activation of a cysteine protease in MCF-7 and T47D breast cancer cells during beta-lapachone-mediated apoptosis. Exp Cell Res 2000; 255:144-155.
6. Blanco E, Bey EA, Dong Y, Weinberg BD, Sutton DM, Boothman DA, Gao J. Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells. J Control Release 2007;122:365-374.
7. Dong Y, Chin SF, Blanco E, Bey EA, Kabbani W, Xie XJ, Bornmann WG, Boothman DA, Gao J. Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy. Clin Cancer Res 2009;15:131-139.
8. Begleiter A, Fourie J. Induction of NQO1 in cancer cells. Methods Enzymol 2004;382:320-351.
9. Rauth AM, Goldberg Z, Misra V. DT-diaphorase: Possible roles in cancer chemotherapy and carcinogenesis. Oncol Res 1997:9:339-349.
10. Ross D, Siegel D. NAD(P)H:Quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol 2004;382:115-144.
11. Siegel D, Beall H, Senekowitsch C, Kasai M, Arai H, Gibson NW, Ross D. Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry 1992;31:7879-7885.
12. Robertson N, Stratford IJ, Houlbrook S, Carmichael J, Adams GE. The sensitivity of human tumour cells to quinone bioreductive drugs: What role for DT-diaphorase? Biochem Pharmacol 1992:44:409-412.
13. Loadman PM, Bibby MC, Phillips RM. Pharmacological approach towards the development of indolequinone bior-eductive drugs based on the clinically inactive agent EO9. Br J Pharmacol 2002;137:701-709.
14. Colucci MA, Moody CJ, Couch GD. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: From synthetic organic chemistry to com-pounds with anticancer potential. Org Biomol Chem 2008; 6:637-656.
15. Duvoix A, Delhalle S, Blasius R, Schnekenburger M, Morceau F, Fougère M, Henry E, Galteau MM, Dicato M, Diederich M. Effect of chemopreventive agents on glutathione S-transferase P1-1 gene expression mechanisms via activating protein 1 and nuclear factor kappa B inhibition. Biochem Pharmacol 2004;68:1101-1111.
16. Begleiter A, Leith MK, Thliveris JA, Digby T. Dietary induction of NQO1 increases the antitumour activity of mitomycin C in human colon tumours in vivo. Br J Cancer 2004;91:1624-1631.
17. Beall HD, Murphy AM, Siegel D, Hargreaves RH, Butler J, Ross D. Nicotinamide adenine dinucleotide (phosphate): Quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: Quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol 1995;48:499-504.
18. Keyes SR, Fracasso PM, Heimbrook DC, Rockwell S, Sligar SG, Sartorelli AC Role of NADPH:Cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C1. Cancer Res 1984;44:5638-5643.
19. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: Correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 1996;88:259-269.
20. Dehn DL, Winski SL, Ross D. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor qui-nones: Evaluation of the activity of RH1. Clin Cancer Res 2004;10:3147-3155.
21. Siegel D, Franklin WA, Ross D. Immunohistochemical detection of NAD(P)H:Quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res 1998;4:2065-2070.
22. Belinsky M, Jaiswal AK. NAD(P)H:Quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev 1993;12:103-117.
23. Olive PL, Banáth JP. Phosphorylation of histone H2AX as a measure of radiosensitivity. Int J Radiat Oncol Biol Phys 2004;58:331-335.
24. Bentle MS, Reinicke KE, Bey EA, Spitz DR, Boothman DA. Calcium-dependent modulation of poly(ADP-ribose)poymer-ase-1 alters cellular metabolisms and DNA repair. J Biol Chem 2006;281:33684-33696.
25. Choi EK, Terai K, Ji IM, Kook YH, Park KH, Oh ET, Griffin RJ, Lim BU, Kim JS, Lee DS, et al. Upregulation of NAD(P)H:Quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells. Neoplasia 2007;9:634-642.
26. Terai K, Dong GZ, Oh ET, Park MT, Gu Y, Song CW, Park HJ. Cisplatin enhances the anticancer effect of beta-lapachone by upregulating NQO1. Anticancer Drugs 2009; 20:901-909.
27. Takahashi A, Matsumoto H, Nagayama K, Kitano M, Hirose S, Tanaka H, Mori E, Yamakawa N, Yasumoto J, Yuki K, et al. Evidence for the involvement of double-strand breaks in heat-induced cell killing. Cancer Res 2004;64: 8839-8845.
28. Hunt CR, Pandita RK, Laszlo A, Higashikubo R, Agarwal M, Kitamura T, Gupta A, Rief N, Horikoshi N, Baskaran R, et al. Hyperthermia activates a subset of ataxia-telangiectasis mutated effectors independent of DNA strand breaks and heat shock protein 70 status. Cancer Res 2007;67:2010-3017.
29. Laszlo A. Fleischer I. Heat-induced perturbations of DNA damage signaling pathways are modulated by molecular chaperones. Cancer Res 2009;69:2042-2049.
30. Laszlo A, Fleischer I. The heat-induced gamma-H2AX response does not play a role in hyperthermic cell killing 2009;25:199-209.
31. Jone EL, Oleson JR, Prosnitz LR, Samulski TV, Vujaskovic Z, Yu D, Sanders LL, Dewhirst MW. Randomized trial of hyperthermica and radiation for superficial tumors. J Clin Oncol 2005;23:3079-3085.
32. van der Zee J, Gonzalez Gonalez D, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA. Comparison of radiother-apy alone with radiotherapy plus hyperthermia in coally advanced pelvic tumours: A prospective radomised, multi-centre trial. Dutch Deep Hyperthermia Group. Lancet 2000;355:1119-11125.
33. Issels RD. Hyperthermia adds to chemotherapy. Eur J Cancer 2008;44:2546-2554.
34. Song CW, Park HJ, Griffin RJ. Improvement of tumor oxygenation by mild hyperthermia. Radiat Res 2001;155: 515-528.
35. Park HJ, Choi EK, Choi J, Ahn KJ, Kim EJ, Ji IM, Kook YH, Ahn SD, Williams B, Griffin R, Boothman DA, Lee CK, Song CW. Heat-induced up-regulation of NAD(P)H Quinone oxidoreductase potentiates anticancer effects of beta-lapachone. Clin Cancer Res 2005;11:8866-8871.
36. Song CW, Chae JJ, Choi EK, Hwang TS, Kim C, Lim BU, Park HJ. Anti-cancer effect of bio-reductive drug beta-lapachone is enhanced by activating NQO1 with heat shock. Int J Hyperthermia 2008;24:161-169.
37. Fletcher CDM, Unni KK, Mertens F. Conventional osteo-sarcoma. In: Raymond AK, Ayala AG, and Knuutila S, editors. World Health Organization classification of tumors. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002. pp 264-270.
38. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006;106: 1154-1161.
39. Liu TJ, Lin SY, Chau YP. Inhibition of poly (ADP-ribose) polymerase activation attenuates beta-lapachone-induced necrotic cell death in human osteosarcoma cells. Toxicol Appl Pharmacol 2002;182:116-125.
40. Park HJ, Lyon JC, Ohtsubo T, Song CW. Cell cycle progression and apoptosis after irradiation in an acidic environment. Cell Death Diff 2000;7:202-207.